Zhang, Jianrong https://orcid.org/0000-0003-4688-5222
Zhang, Yiyin
Tang, Shiyan
Jiang, Long
He, Qihua
Hamblin, Lindsey Tristine
He, Jiaxi
Xu, Zhiheng
Wu, Jieyu
Chen, Yaoqi
Liang, Hengrui
Chen, Difei
Huang, Yu
Wang, Xinyu
Deng, Kexin
Jiang, Shuhan
Zhou, Jiaqing
Xu, Jiaxuan
Chen, Xuanzuo
Liang, Wenhua https://orcid.org/0000-0002-1391-8238
He, Jianxing
Clinical trials referenced in this document:
Documents that mention this clinical trial
Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour
https://doi.org/10.1136/bmjopen-2017-017240
Documents that mention this clinical trial
Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour
https://doi.org/10.1136/bmjopen-2017-017240
Documents that mention this clinical trial
Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour
https://doi.org/10.1136/bmjopen-2017-017240
Documents that mention this clinical trial
Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour
https://doi.org/10.1136/bmjopen-2017-017240
Documents that mention this clinical trial
Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour
https://doi.org/10.1136/bmjopen-2017-017240
Documents that mention this clinical trial
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
https://doi.org/10.1016/j.ejca.2011.05.007
Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour
https://doi.org/10.1136/bmjopen-2017-017240
Documents that mention this clinical trial
Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour
https://doi.org/10.1136/bmjopen-2017-017240
Documents that mention this clinical trial
Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond
https://doi.org/10.1016/j.ejca.2013.06.027
Efficacy of nivolumab plus relatlimab versus BRAF/MEK inhibitors for first-line treatment of
<i>BRAF</i>
-mutant advanced melanoma: A matching-adjusted indirect comparison
https://doi.org/10.1136/bmjonc-2025-000912
In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma
https://doi.org/10.1136/jitc-2019-000204
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
https://doi.org/10.1016/s0140-6736(15)60898-4
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma
https://doi.org/10.1016/j.ejca.2015.03.004
Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour
https://doi.org/10.1136/bmjopen-2017-017240
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
https://doi.org/10.1016/s0140-6736(12)60868-x
Documents that mention this clinical trial
Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour
https://doi.org/10.1136/bmjopen-2017-017240
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
https://doi.org/10.1016/s0140-6736(11)61742-x
Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin
https://doi.org/10.1136/gut.2009.204453
Documents that mention this clinical trial
Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour
https://doi.org/10.1136/bmjopen-2017-017240
Documents that mention this clinical trial
Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour
https://doi.org/10.1136/bmjopen-2017-017240
Documents that mention this clinical trial
Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour
https://doi.org/10.1136/bmjopen-2017-017240
Documents that mention this clinical trial
Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?
https://doi.org/10.1016/j.ejca.2015.10.006
An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer
https://doi.org/10.1016/j.ejca.2012.05.022
Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour
https://doi.org/10.1136/bmjopen-2017-017240
Documents that mention this clinical trial
Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour
https://doi.org/10.1136/bmjopen-2017-017240
Documents that mention this clinical trial
Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour
https://doi.org/10.1136/bmjopen-2017-017240
Documents that mention this clinical trial
Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour
https://doi.org/10.1136/bmjopen-2017-017240
Documents that mention this clinical trial
Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour
https://doi.org/10.1136/bmjopen-2017-017240
Documents that mention this clinical trial
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
https://doi.org/10.1016/s0140-6736(11)60070-6
Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour
https://doi.org/10.1136/bmjopen-2017-017240
Documents that mention this clinical trial
Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer
https://doi.org/10.1016/j.lungcan.2010.08.018
Targeted therapies for non-small cell lung cancer
https://doi.org/10.1016/j.lungcan.2009.10.012
Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour
https://doi.org/10.1136/bmjopen-2017-017240